tbuckley/cabot-search huggingface dataset:
Rheumatoid arthritis: pathogenesis and therapeutic advances
Authors: Ying Gao, Yunkai Zhang, Xingguang Liu
Journal: MedComm (2024)

Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the unresolved synovial inflammation for tissues‐destructive consequence, which remains one of significant causes of disability and labor loss, affecting about 0.2–1% global population. Although treatments with disease‐modifying antirheumatic drugs (DMARDs) are effective to control inflammation and decrease bone destruction, the overall remission rates of RA still stay at a low level. Therefore, uncovering the pathogenesis of RA and expediting clinical transformation are imminently in need. Here, we summarize the immunological basis, inflammatory pathways, genetic and epigenetic alterations, and metabolic disorders in RA, with highlights on the abnormality of immune cells atlas, epigenetics, and immunometabolism. Besides an overview of first‐line medications including conventional DMARDs, biologics, and small molecule agents, we discuss in depth promising targeted therapies under clinical or preclinical trials, especially epigenetic and metabolic regulators. Additionally, prospects on precision medicine based on synovial biopsy or RNA‐sequencing and cell therapies of mesenchymal stem cells or chimeric antigen receptor T‐cell are also looked forward. The advancements of pathogenesis and innovations of therapies in RA accelerates the progress of RA treatments.
A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancer
Authors: Shiwen Huo, Jinqi Xue, Shuo Wang, Huilian Shan, Guanglei Chen, Nan Niu, Yimin Wang, Fang Qiu, Yi Zhao, Fei Xing, Xinyu Zheng, Wei Tu, Ke Li, Hai Zhao, Meiyue Tang, Qianshi Xu, Chao Liu, Yafei Zhao, Xiaofan Jiang, Zheng Pang, Keliang Zhang, Dianlong Zhang, Zhe‐Sheng Chen, Caigang Liu
Journal: MedComm (2024)

Abstract Triple‐positive breast cancer (TPBC) poorly responds to current standard neoadjuvant therapy (trastuzumab plus pertuzumab and chemotherapy). Our previous MUKDEN 01 study showed a promising total pathological complete response (tpCR) rate of 30.4% with neoadjuvant pyrotinib (pan‐human epidermal growth factor receptor tyrosine kinase inhibitor) plus dalpiciclib (cyclin‐dependent kinase 4/6 inhibitor) and letrozole, but the efficacy remains suboptimal. This pilot study (NCT05228951) explored adding trastuzumab to this triplet neoadjuvant regimen in patients with stage II–III TPBC. The primary endpoint was tpCR (ypT0/is, ypN0) rate. Between February 2022 and June 2022, 12 patients were enrolled, and seven (58%; 95% confidence interval [CI], 27.7%–84.8%) patients achieved tpCR. The rate of residual cancer burden (RCB) 0–I was 75% (95% CI, 46.8%–91.1%). The objective response rate (ORR) was 92% (95% CI, 64.6%–98.5%). Mean Ki‐67 level was significantly reduced from 45.0% (95% CI, 19.5%–70.5%) at baseline to 17.2% (95% CI, 0.7%–33.7%) after neoadjuvant therapy ( p = 0.03). The most common grade 3 adverse events were diarrhea (four [33%]) and decreased neutrophil count (three [25%]). No grade 4 adverse events or treatment‐related deaths occurred. This four‐drug neoadjuvant regimen shows promising pathological response with an acceptable safety profile in patients with TPBC. A randomized controlled trial (NCT05638594) of this regimen is being conducted.
Deep learning for precise diagnosis and subtype triage of drug‐resistant tuberculosis on chest computed tomography
Authors: Shufan Liang, Xiuyuan Xu, Zhe Yang, Qiuyu Du, Lingyu Zhou, Jun Shao, Jixiang Guo, Binwu Ying, Weimin Li, Chengdi Wang
Journal: MedComm (2024)

Abstract Deep learning, transforming input data into target prediction through intricate network structures, has inspired novel exploration in automated diagnosis based on medical images. The distinct morphological characteristics of chest abnormalities between drug‐resistant tuberculosis (DR‐TB) and drug‐sensitive tuberculosis (DS‐TB) on chest computed tomography (CT) are of potential value in differential diagnosis, which is challenging in the clinic. Hence, based on 1176 chest CT volumes from the equal number of patients with tuberculosis (TB), we presented a Deep learning‐based system for TB drug resistance identification and subtype classification (DeepTB), which could automatically diagnose DR‐TB and classify crucial subtypes, including rifampicin‐resistant tuberculosis, multidrug‐resistant tuberculosis, and extensively drug‐resistant tuberculosis. Moreover, chest lesions were manually annotated to endow the model with robust power to assist radiologists in image interpretation and the Circos revealed the relationship between chest abnormalities and specific types of DR‐TB. Finally, DeepTB achieved an area under the curve (AUC) up to 0.930 for thoracic abnormality detection and 0.943 for DR‐TB diagnosis. Notably, the system demonstrated instructive value in DR‐TB subtype classification with AUCs ranging from 0.880 to 0.928. Meanwhile, class activation maps were generated to express a human‐understandable visual concept. Together, showing a prominent performance, DeepTB would be impactful in clinical decision‐making for DR‐TB.
Targeting the organelle for radiosensitization in cancer radiotherapy
Authors: Xiaoyan Sun, Linjie Wu, Lina Du, Wenhong Xu, Min Han
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Radiotherapy is a well-established cytotoxic therapy for local solid cancers, utilizing high-energy ionizing radiation to destroy cancer cells. However, this method has several limitations, including low radiation energy deposition, severe damage to surrounding normal cells, and high tumor resistance to radiation. Among various radiotherapy methods, boron neutron capture therapy (BNCT) has emerged as a principal approach to improve the therapeutic ratio of malignancies and reduce lethality to surrounding normal tissue, but it remains deficient in terms of insufficient boron accumulation as well as short retention time, which limits the curative effect. Recently, a series of radiosensitizers that can selectively accumulate in specific organelles of cancer cells have been developed to precisely target radiotherapy, thereby reducing side effects of normal tissue damage, overcoming radioresistance, and improving radiosensitivity. In this review, we mainly focus on the field of nanomedicine-based cancer radiotherapy and discuss the organelle-targeted radiosensitizers, specifically including nucleus, mitochondria, endoplasmic reticulum and lysosomes. Furthermore, the organelle-targeted boron carriers used in BNCT are particularly presented. Through demonstrating recent developments in organelle-targeted radiosensitization, we hope to provide insight into the design of organelle-targeted radiosensitizers for clinical cancer treatment.
Nasopharyngeal microbiota in children is associated with severe asthma exacerbations
Authors: Gina J van Beveren, Wouter A A de Steenhuijsen Piters, Shelley A Boeschoten, Sam Louman, Mei Ling Chu, Kayleigh Arp, Pieter L Fraaij, Matthijs de Hoog, Corinne Buysse, Marlies A van Houten, Elisabeth A M Sanders, Peter J F M Merkus, Annemie L Boehmer, Debby Bogaert
Journal: Journal of Allergy and Clinical Immunology (2024)

The respiratory microbiome has been associated with the etiology and disease course of asthma.
Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer
Authors: R. Servant, R. Parmentier, R. Dolgos, J. Wang, Z. Diamantopoulou, L. Roma, F. Stenner, A.J. Templeton, N. Aceto, L. Bubendorf, H. Seifert, C.A. Rentsch, C. Le Magnen
Journal: European Urology (2024)
Preclinical assessment of integrin receptors as therapeutic targets in advanced treatment-resistant prostate cancer
Authors: I. Tsaur, M. Saar, E. Juengel, O. Vakhrusheva, K.S. Slade, M. Michaelis, F. Rothweiler, J. Cinatl, M.D. Menger, J. Linxweiler, R.A. Blaheta
Journal: European Urology (2024)
Validation of FGFR screening by uromonitor and therascreen in FFPE tissue in bladder cancer in the context of the clinical-pathological real-world registry study “Bladder BRIDGister”
Authors: T. Ecke, E. Veltrup, F. Linden, H. Prazeres, J. Brás, C. Dias, R. Hake, S. Eidt, J. Vinagre, P. Soares, S. Koch, J. Roggisch, D. Barski, A. Gössl, T. Otto, M. May, A. Kravchuk, N. Gagel, F. Friedersdorff, L. Sommerfeldt, R. Stöhr, R. Wirtz
Journal: European Urology (2024)
Ureteroenteric strictures of open vs robot-assisted radical cystectomy with totally intracorporeal urinary diversion: Single centre prospective randomised controlled trial
Authors: R. Mastroianni, G. Tuderti, U. Anceschi, A.M. Bove, A. Brassetti, S. D’Annunzio, M. Ferriero, L. Misuraca, S. Guaglianone, G. Simone
Journal: European Urology (2024)
Clinical significance of SCHLAP1:UBE2E3 gene fusion compared to TMPRSS2:ERG gene fusion in localized prostate cancer: Insights from a Korean cohort
Authors: B. Kang, S.H. Kim, K.H. Jang, W.S. Seong, K.H. Kim, H.K. Ha, C.H. Lee, H.S. Lee
Journal: European Urology (2024)
Risk of upper urinary tract dissemination in cT3 bladder cancer patients treated with Double J stent versus nephrostomy tube prior to radical cystectomy
Authors: M. De Angelis, F. Soria, B. Pradere, L. Afferi, F. Montorsi, A. Briganti, S. Shariat, P. Wiklund, D. D’Andrea, S. Albissini, A. Mari, F. Del Giudice, W. Krajewski, E. Laukhtina, J.Y-C. Teoh, K. Mori, L.S. Mertens, A. Gallioli, R. Pichler, A. Cimadamore, M. Moschini
Journal: European Urology (2024)
Central venous access and the risk for thromboembolic events in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer
Authors: Y.A.M. Huge, H. Rydell, V. Eriksson, M. Johansson, F. Alamdari, J. Svensson, F. Aljabery, A.M. Sherif
Journal: European Urology (2024)
Does pre-cystectomy anemia following neoadjuvant chemotherapy in muscle invasive bladder cancer affect survival?
Authors: V. Eriksson, J. Elfving-Long, M. Johansson, Y.A.M. Huge, F. Alamdari, F. Aljabery, J. Svensson, V. Banday, A.M. Sherif
Journal: European Urology (2024)
PSA response after radiotherapy. Is there a definition of PSA persistence after RT?
Authors: U.G. Falagario, F. Pellegrino, A. Abbadi, L. Björnebo, A. Valdman, G. Carrieri, A. Briganti, F. Montorsi, O. Akre, M. Aly, M. Eklund, T. Nordström, H. Grönberg, P. Wiklund, A. Lantz
Journal: European Urology (2024)
Stapled W-shaped Hautmann orthotopic ileal neobladder. Functional results and complications over a 13-year period
Authors: A. Cormio, N. d’Altilia, B. Calò, U.G. Falagario, F. Cinelli, V. Mancini, G.M. Busetto, C. Bettocchi, G. Carrieri, L. Cormio
Journal: European Urology (2024)
Stage-specific recurrence rates post-radical cystectomy: A path to personalized oncological follow-up
Authors: M.S. Wettstein, L. Antonelli, A. Martini, E. Bologna, G. Guano, A. Veccia, K. Tully, P. Umari, C. Pochet, L. Lambertini, R. Pichler, N. Pavan, J.Y-C. Teoh, G.B. Schulz, F. Soria, U. Bieri, M. Alrumayyan, M. Rink, C. Lonati, F. Sessa, M. Roupret, L. Lavallee, M. Moschini, C.D. Fankhauser
Journal: European Urology (2024)
Outcomes of invasive primary urethral cancer in women: An analysis from the national cancer database
Authors: M.A. Ganiyani, V. Podder, A. Pon Avudaiappan, A.A. Khosla, P. Prabhakar, A. Ozair, S. Ahmad, M. Rubens, M. Roy, M. Manoharan, R. Garje
Journal: European Urology (2024)
Treatment strategies and survival outcomes in Non-invasive Primary Urethral Cancer (NPUC): A comprehensive analysis from a large database
Authors: M.A. Ganiyani, V. Podder, A.A. Khosla, S. Ahmad, A. Pon Avudaiappan, A. Ozair, P. Prabhakar, M. Roy, M. Rubens, M. Manoharan, R. Garje
Journal: European Urology (2024)
Enhancing patient selection for salvage radical prostatectomy: A new risk-stratification model from a large retrospective cohort
Authors: G. Calleris, G. Marra, N. Benfant, P. Rajwa, M. Ahmed, A. Ghoreifi, A. Abreu, L. Ribeiro, T. Westhofen, R. Tourinho-Barbosa, Y. Raskin, J.A. Smith, M. Oderda, H. Van Der Poel, S. Joniau, R. Sanchez-Salas, A. Kretschmer, P. Cathcart, I. Gill, R.J. Karnes, D. Tilki, S.F. Shariat, K. Touijer, P. Gontero
Journal: European Urology (2024)
Age-dependent effect of early salvage radiotherapy for biochemical recurrence in prostate cancer patients treated with radical prostatectomy
Authors: A. Pellegrino, F. Barletta, G. Gandaglia, S. Scuderi, P. Scilipoti, M. Longoni, A. Stabile, D. Cannoletta, L. Quarta, E. Mazzone, A. Viti, A. Santangelo, P. Zaurito, R. Leni, G.O. Cirulli, V. Cucchiara, D. Robesti, F. Montorsi, A. Briganti
Journal: European Urology (2024)
Standardized assessment of Perioperative outcomes of robot-assisted radical cystectomy assessed using the EAU guidelines for collecting and reporting complications
Authors: F. Pellegrino, C. Re, P. Scilipoti, M. Longoni, M. De Angelis, G. Burgio, L. Quarta, G. Musso, G. Avesani, R. Leni, G. Basile, G. Rosiello, G. Gandaglia, U. Capitanio, A. Necchi, D. Raggi, R. Lucianò, O. Akre, P. Wiklund, R. Colombo, A. Salonia, M. Francesco, A. Briganti, M. Moschini
Journal: European Urology (2024)
Comparison of EAU and EMBARK criteria for high-risk biochemical recurrence after radical prostatectomy
Authors: G. Server Gomez, A. Coy García, A. Lopez Abad, J.P. Loyola Maturana, I.S. Giménez Andreu, I. Guardiola Ruiz, P. de Pablos Rodríguez, J. Boronat Catalá, J. Casanova Ramón-Borja, A. Gómez-Ferrer, A. Collado Serra, A. Calatrava Fons, M. Ramirez Backhaus
Journal: European Urology (2024)
Is strict PSA Surveillance necessay for patients with a negative PI-RADS 4 lesion following MRI-Fusion targeted and saturation biopsies of prostate
Authors: W.C. Tsang, K.W. Lai, J. Ong, K.Y. Wang, A. Quek, D. Chong, Q.H. Wu, E. Chiong
Journal: European Urology (2024)
Current clinical practice patterns with robotic salvage radical prostatectomy: Oncological results from 10 high-volume robotic centers
Authors: M. Wenzel, F. Di Maida, J. Gomez Rivas, L. Ibanez, C.A. Bravi, R. De Groote, F. Piramide, F. Turri, K. Kowalczyk, C. Würnschimmel, G. Sharma, I. Andras, E. Lambert, N. Liakos, D. Darlington, M. Paciotti, G. Sorce, A. Galfano, P. Dell’Oglio, A. Mottrie, V. Patel, F. Chun, M.C. Moschovas, A. Larcher
Journal: European Urology (2024)
Surgical and oncological outcomes of salvage radical prostatectomy after focal therapies: A matched-pair analysis
Authors: F. Ambrosini, J. Hagemann, Y. Nagaraj, R. Pose, T. Maurer, H. Heinzer, U. Michl, T. Steuber, L. Budäus, C. Terrone, P. Tennstedt, A. Haese, D. Tilki, M. Graefen, G. Salomon
Journal: European Urology (2024)
Tertiary lymphoid structures in retroperitoneal sarcoma correlates with improved prognosis
Authors: H. Kokubun, A. Takada-Owada, T. Kijima, M. Kotouno, K. Goto, D. Mamiya, H. Shimoda, N. Okubo, R. Kurashina, T. Uematsu, K. Takei, H. Betsunoh, M. Yashi, K. Ishida, T. Kamai
Journal: European Urology (2024)
Molecular detection of SARS-CoV-2 and other respiratory viruses in saliva and classroom air: a two winters tale
Authors: Nicolas Banholzer, Pascal Bittel, Philipp Jent, Lavinia Furrer, Kathrin Zürcher, Matthias Egger, Tina Hascher, Lukas Fenner
Journal: Clinical Microbiology and Infection (2024)

ObjectivesTo compare the prevalence of SARS-CoV-2 and other respiratory viruses in saliva and bioaerosols between two winters and model the probability of virus detection in classroom air for different viruses.MethodsWe analyze saliva, air, and air cleaner filter samples from studies conducted in two Swiss secondary schools (age 14-17 years) over seven weeks during the winters of 2021/22 and 2022/23. Two bioaerosol sampling devices and HEPA filters from air cleaners were used to collect airborne virus particles in five classrooms. Daily bioaerosol samples were pooled for each sampling device before PCR analysis of a panel of 19 respiratory viruses and viral subtypes. The probability of detection of airborne viruses was modelled using an adjusted Bayesian logistic regression model.ResultsThree classes (58 students) participated in 2021/22, and two classes (38 students) in 2022/23. During winter 2021/22, SARS-CoV-2 dominated in saliva (19 of 21 positive samples) and bioaerosols (9 of 10). One year later, there were 50 positive saliva samples, mostly influenza B, rhinovirus, and adenovirus, and two positive bioaerosol samples, one rhinovirus and one adenovirus. The weekly probability of airborne detection was 34% (95%-credible interval [CrI] 22%−47%) for SARS-CoV-2 and 10% (95%-CrI 5%-16%) for other respiratory viruses.ConclusionsThere was a distinct shift in the distribution of respiratory viruses from SARS-CoV-2 during the Omicron wave to other respiratory viruses one year later. SARS-CoV-2 is more likely to be detected in the air than other endemic respiratory viruses, possibly reflecting differences in viral characteristics and the composition of virus-carrying particles that facilitate airborne long-range transmission.
First description of a collagen score outperforming PSA, age and mpMRI in diagnosis of significant prostate cancer
Authors: I. Heidegger, M. Frantzi, S. Salcher, P. Tymoszuk, E. Gomez-Gomez, G. Lendinez Cano, H. Mischak, A. Vlahou, A. Pircher
Journal: European Urology (2024)
Advancing prostate cancer risk stratification: Is predicting positive Magnetic Resonance Imaging (MRI) findings the preferred approach?
Authors: M.J. Hagens, L.S. Mertens, K. Barwari, N. Aben, J. Stárková, V. Struben, T.N. Boellaard, S.W.T.J.P. Heijmink, M.C. Van Dijk - De Haan, J. Van Kesteren, L.C. Van Maaren, E. Van Muilekom, J. Visser, H.G. Van Der Poel, P.J. Van Leeuwen
Journal: European Urology (2024)
Epidermal growth factor-like domain 7 inhibit immune response in metastatic castration resistant prostate cancer by de-activation of endothelial intercellular adhesion molecule-1
Authors: Y.H. Lee, J.Y. Kim, S. Yoo, D. Lee, S.S. Lee, W.H. Song, J.K. Nam, S-W. Park
Journal: European Urology (2024)
Testing free PSA percentage as a tool in predicting future risk of developing prostate cancer: A system wide analysis of a contemporary North American cohort
Authors: G.O. Cirulli, M. Finati, G. Chiarelli, A. Stephens, M. Davis, C. Morrison, S. Tinsley, P. Etta, M. Butaney, A. Sood, G. Lughezzani, N. Buffi, G. Carrieri, A. Salonia, A. Briganti, F. Montorsi, C. Rogers, F. Abdollah
Journal: European Urology (2024)
Comparing the performance of digital rectal examination and PSA as a screening test for prostate cancer: A systematic review and meta-analysis
Authors: A. Matsukawa, T. Yanagisawa, K. Bekku, M.K. Parizi, E. Laukhtina, J. Klemm, S. Chiujdea, M. Keiichiro, S. Kimura, T. Fazekas, M. Miszczyk, J. Miki, T. Kimura, P. Karakiewicz, P. Rajwa, S. Shariat
Journal: European Urology (2024)
Identification of novel snoRNA-based biomarkers from urine-derived extracellular vesicles for non-invasive detection of clear cell renal cell carcinoma
Authors: K. Grützmann, K. Salomo, A. Krüger, A. Lohse-Fischer, K. Erdmann, M. Seifert, G. Baretton, D. Aust, E. Schröck, C. Thomas, S. Füssel
Journal: European Urology (2024)
Investigation of the tumor-macrophage crosstalk to identify palmitic acid as modulator of macrophage reprogramming in prostate cancer
Authors: G. Lughezzani, G. Marelli, N.M. Buffi, P. Casale, A. Saita, R. Hurle, V. Fasulo, M. Paciotti, A. Finocchiaro, P. Colombo, G.M. Maria, R. Carriero, M. Iovino, P. Kundefranco, C. Morosi, D. Di Mitri, M. Lazzeri
Journal: European Urology (2024)
FINPRO – a nationwide registry study on localized prostate cancer in Finland
Authors: T. Murtola, T. Hakkarainen, M. Lahelma, P. Pennanen, M. Pietilä, P. Hervonen, O. Kääriäinen, H. Minn, T. Nykopp, H. Ronkainen, O. Ettala, A.S. Rannikko
Journal: European Urology (2024)
Gene expression-based molecular classifier is associated with biochemical recurrence and proves independent of heterogeneity in primary prostate cancer
Authors: K. Axcrona, B. Johannessen, T. Myklebust, A.C. Bakken, A.M.V. Maltau, M. Jareid, R.A. Lothe, U. Axcrona, R.I. Skotheim
Journal: European Urology (2024)
Does multiparametric (mp) MRI and MRI-informed biopsy improve risk allocation of men at inclusion in active surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial
Authors: C. Marenghi, F. Badenchini, T. Rancati, B. Avuzzi, A. Messina, A. Casale, M.A. Catanzaro, M. Claps, A. Casbarra, B. Noris Chiorda, V. Guadalupi, M. Stellato, S. Nazzani, S. Stagni, L. Cattaneo, A. Macchi, S. Villa, T. Torelli, E. Verzoni, A. Tesone, G. Procopio, N. Nicolai
Journal: European Urology (2024)
Conditional cancer-specific survival in surgically treated retroperitoneal liposarcoma and leiomyosarcoma patients: A stage-specific analysis
Authors: A. Baudo, L. Scheipner, L.M.I. Jannello, M. de Angelis, C. Siech, F. Di Bello, S. Morra, Z. Tian, P. Acquati, S. Ahyai, O. de Cobelli, A. Briganti, F. Chun, N. Longo, F. Saad, S. Shariat, L. Carmignani, P. Karakiewicz
Journal: European Urology (2024)
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
Authors: M. Villa, G. Cazzaniga, M. Bolognesi, V. Crippa, F. Malighetti, A. Aroldi, D. Perri, F. Mazzoleni, G. Bozzini, F. Pagni, R. Piazza, L. Mologni, D. Ramazzotti
Journal: European Urology (2024)
Identification of new therapeutic targets in penile squamous cell carcinoma using patient-derived in-vitro and in-vivo models
Authors: J. Linxweiler, H. Ayoubian, J. Mink, P. Pongratanakul, M.A. Skowron, M. Kotthoff, M. Stöckle, D. Nettersheim, K. Junker
Journal: European Urology (2024)
PARP Inhibitor Plus Androgen Receptor Pathway inhibitor combinations for 1st line mCRPC: A systematic review and meta-analysis
Authors: R.K. Sayyid, Z. Klaassen, A. Berlin, S. Roy, R. Bernardino, J. Chavarriaga, D.M. Jiang, D.E. Spratt, N.E. Fleshner, C.J.D. Wallis
Journal: European Urology (2024)
HIFI-2 study: Salvage HIFU for local recurrence after first-line radiotherapy for localized prostate cancer in 531 patients
Authors: P. Rischmann, G. Ploussard, T. Chevallier, G. Fiard, R. Mathieu, N. Houédé, A. Villers, P. Coloby
Journal: European Urology (2024)
Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis
Authors: T. Yanagisawa, F. Quhal, T. Kawada, E. Laukhtina, P. Rajwa, M. Von Deimling, B. Pradere, K. Mori, T. Kimura, M. Schmidinger, S.F. Shariat
Journal: European Urology (2024)
Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer - a Swedish retrospective multicenter study
Authors: V. Eriksson, J. Holmlund, E. Wiberg, M. Johansson, Y.A.M. Huge, F. Alamdari, J. Svensson, F. Aljabery, A.M. Sherif
Journal: European Urology (2024)
Identify the optimal candidates for adjuvant androgen deprivation therapy among patients with detectable PSA after radical prostatectomy
Authors: F. Pellegrino, U.G. Falagario, S. Knipper, A. Martini, O. Akre, M. Aly, M.C. Moschovas, C.A. Bravi, J. Tran, Y. Heiniger, A. Von Kempis, R. Schaffar, G. Carrieri, A. Briganti, F. Montorsi, C-H. Rochat, A. Mottrie, T.E. Ahlering, H. John, V. Patel, M. Graefen, P. Wiklund
Journal: European Urology (2024)
Clinical translation of the albumin-binding radioligand 177Lu-(S)-Ibu-DAB-PSMA in patients with mCRPC: Enhancing clinical efficacy of PSMA-targeted RLT
Authors: R. Fernandez, H. Nicolai, P. Ritt, C. Soza-Ried, A. Rogers, Y. Qin, M. Meckel, F. Fliegert, M. Ceballos, J. Wettlin, H. Amaral, K. Zhernosekov, F. Borgna, L.M. Deberle, R. Schibli, C. Müller, C. Martinez, C. Del Castillo, V. Kramer
Journal: European Urology (2024)
Effects of preoperative treatment with phenolmicine p3 and Boisexil dietary supplement on postoperative irritative symptoms in patients with middle prostate volume undergoing transurethral prostate surgery
Authors: A. Antonioni, F.M. Valenzi, O.A. Rera, G. Martino, D. Graziani, F. Gianfrancesco, G. Candita, M.B. Sequi, P.P. Suraci, S. Scalzo, A. Fuschi, Y. Al Salhi, A. Sciarra, S. Salciccia, G. Franco, G. Di Pierro, G. Tema, C. De Nunzio, A. Carbone, A.L. Pastore
Journal: European Urology (2024)